105211-24-3

Upstream product

• 105189-44-4 3,5-dibromo-N-trifluoroacetyl-L-tyrosine methyl ester 
• 108-95-2 phenol 
• 105190-09-8 3-chloro-6-(2-methoxybenzyl)-pyridazine 
• 105190-15-6 2<6(-chloropyridazin-3-yl)methyl>phenol 
• 105190-16-7 2<(6-chloropyridazin-3-yl)methyl>4,6-di-t-butylphenol 

Downstream Products

• 105190-17-8 L-3,5-dibromo-3'-<(6-oxo-1,6-dihydropyridazin-3-yl)methyl>-5'-t-butyl-N-trifluoroacetylthyronine methyl ester 
• 105170-49-8 D-3,5-dibromo-3'-<(6-oxo-1,6-dihydropyridazin-3-yl)methyl>thyronine 
• 105211-23-2 SKF 94901 

Relevant academic research and scientific papers

Use of src SH2 specific compounds to treat a bone resorption disease

Invented is a method of treating a bone resorption disease in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human src SH2 domain with a binding affinity greater than fifty-fold higher than the binding affinity with which the compound binds to a human lck SH2 domain and a human fyn SH2 domain, and, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such src SH2 domain.

Synthesis of Thyroid Hormone Analogues. Part 2. Oxidative Coupling Approach to SK&F L-94901

Asynthesis of L-3,5-dibromo-3'-thyronine-SK&F L-94901 (1), a novel, selective and potent thyromimetic-is described.The key step in this synthesis involves the formation of a hindered diaryl ether moiety.This paper

Pyridyl and pyridazinyl substituted thyronine compounds having selective thyromimetic activity

This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3''-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine.